Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Report on the global anti-infectives market

MarketResearch.com has announced the addition of Kalorama Information's new report "The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)," to their collection of Healthcare market reports.

4 Nov 2009

NanoLogix files international patent applications for its BioNanoPore microorganism detecting technology

NanoLogix, Inc. announces that the company has recently filed BNP™ (BioNanoPore) national patent applications in China, Japan, India, Brazil, Russia and the EU. These applications were filed in order to obtain intellectual property protection for the company's technology in countries viewed as representing the largest potential international market for BNP rapid detection, a revolutionary sandwiched-membrane Petri-based technology that can reduce microorganism detection times by 100-400%.

4 Nov 2009

Leprosy: Man's persistent companion

For thousands of years an undesirable and persistent companion has been travelling with man wherever he goes. Mycobacterium leprae, the bacterium that causes leprosy, has only one known natural host - mankind.

4 Nov 2009

Lovastatin-synthesizing enzyme successfully reconstituted

Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.

4 Nov 2009

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 7,597,895 entitled "Signal peptides, nucleic acid molecules and methods for treatment of caries" by the U.S. Patent and Trademark Office. This is the third patent to issue protecting Kane Biotech's CSP (Competence Stimulating Peptide) technology.

3 Nov 2009

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

2 Nov 2009

MRSA bloodstream infection linked to high mortality rate

A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study.

2 Nov 2009

Bacteria use a well-studied communication system to resist antibiotics

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

1 Nov 2009

Dialysis patients at increased risk of infections during travel: Study

If you're sick, traveling to a foreign land may boost your spirits, but jeopardize your health, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. The findings indicate that dialysis patients who travel on vacation risk infections, anemia, and other complications that can compromise their dialysis treatments.

31 Oct 2009

Four abstracts on RSV and influenza prevention in pediatric health to be presented

MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.

31 Oct 2009

Patients who acquire SSTIs in healthcare settings may stay longer in hospitals to control the infection

Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.

31 Oct 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.

31 Oct 2009

China Medicine announces acquisition of Guangzhou LifeTech Pharmaceuticals

China Medicine Corporation, a developer and leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary supplements, and medical devices and medical formulations, today announced that through its wholly-owned subsidiary in China, Konzern Pharmaceuticals, it has signed an equity transfer agreement (the "Transfer Agreement") to acquire 100% of equity interests in Sinoform Limited.

30 Oct 2009

TGen to secure emergency FDA approval for 2009 H1N1 flu test

The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus.

30 Oct 2009

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.

29 Oct 2009

Antibiotic News and Research

Further Reading

Report on the global anti-infectives market

NanoLogix files international patent applications for its BioNanoPore microorganism detecting technology

Leprosy: Man's persistent companion

Lovastatin-synthesizing enzyme successfully reconstituted

U.S. PTO grants third patent for Kane Biotech's Competence Stimulating Peptide technology

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

MRSA bloodstream infection linked to high mortality rate

Bacteria use a well-studied communication system to resist antibiotics

Dialysis patients at increased risk of infections during travel: Study

Four abstracts on RSV and influenza prevention in pediatric health to be presented

Patients who acquire SSTIs in healthcare settings may stay longer in hospitals to control the infection

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

China Medicine announces acquisition of Guangzhou LifeTech Pharmaceuticals

TGen to secure emergency FDA approval for 2009 H1N1 flu test

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Cempra Pharmaceuticals to present CEM-102 data at the Infectious Diseases Society of America meeting

Antibiotic effects of pumpkin may help fight yeast infections

Cempra Pharmaceuticals stages a presentation on CEM-101

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News